netFormulary
 Report : Medicines with links to NICE 15/08/2020 02:29:09

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Indacaterol & glycopyrrolate inhaler 03.01.04 Formulary NICE New Medicine Evidence Summary 33: indacaterol/glycopyrronium (Ultibro Breezhaler)
Abatacept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Restricted Use NICE TA568 TERMINATED APPRAISAL: Abatacept for treating psoriatic arthritis after DMARDs
Abciximab 02.09 Restricted Use NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Abemaciclib 08.01.05 Restricted Use NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abemaciclib 08.01.05 Restricted Use NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abiraterone 08.03.04.02 Restricted Use NICE TAG 259: Abiraterone for castration resistant prostate cancer
Adalimumab 13.05.03 Restricted Use NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 13.05.03 Restricted Use NICE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 13.05.03 Restricted Use NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa.
Adalimumab 10.01.03 Restricted Use NICE TA373: Adalimumab for JIA
Adalimumab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Adalimumab 10.01.03 Restricted Use NICE TA130: Rheumatoid arthritis
Adalimumab 10.01.03 Restricted Use NICE TA143: Ankylosing spondylitis
Adalimumab 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Adalimumab 10.01.03 Restricted Use NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 11.99.99.99 Restricted Use NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Adefovir Dipivoxil 05.03.03.01 Non Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adefovir Dipivoxil 05.03.03.01 Non Formulary NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a
Afatinib 08.01.05 Restricted Use NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Afatinib 08.01.05 Restricted Use NICE TA444 TERMINATED APPRAISAL: Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy
Aflibercept 08.01.05 Restricted Use NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Restricted Use NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Restricted Use NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Restricted Use NICE TA486: Aflibercept for treating choroidal neovascularisation
Alectinib 08.01.05 Restricted Use NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.03 Restricted Use NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alendronic Acid 06.06.02 Non Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Alendronic Acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Alendronic Acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Alirocumab 02.12 Restricted Use NICE TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alteplase 02.10.02 Restricted Use NICE TA264: Ischaemic stroke (acute) - alteplase
Alteplase 02.10.02 Restricted Use NICE TA264: Alteplase for treating acute ischaemic stroke
Amoxicillin 05.01.01.03 Formulary NICE CG64 Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures
Anakinra 10.01.03 Non Formulary NICE Anakinra - Do not do recommendation
Anti-D (Rh0) Immunoglobulin 14.05.03 Restricted Use NICE TAG156: Anti-D in pregnant women
Apixaban 02.08.02 Restricted Use NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apixaban 02.08.02 Restricted Use NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
Apixaban 02.08.02 Restricted Use NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apremilast 10.01.03 Restricted Use NICE TA433: Apremilast for treating active psoriatic arthritis
Apremilast 13.05.03 Restricted Use NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Aripiprazole 04.02.01 Restricted Use NICE TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder
Aripiprazole 04.02.01 Restricted Use NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Arsenic Trioxide 08.01.05 Restricted Use NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Asfotase alfa 09.08.01 Restricted Use NICE HST6: Asfotase alfa for treating paediatric-onset hypophosphatasia
Ataluren 10.02 Restricted Use NICE HST3: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
Atezolizumab 08.01.05 Restricted Use NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 08.01.05 Restricted Use NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Atezolizumab 08.01.05 Restricted Use NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.01.05 Restricted Use NICE TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Autologous chondrocyte implantation (ACI) 10.04 Restricted Use NICE TA477: Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee
Autologous chondrocyte implantation (ACI) 10.04 Restricted Use NICE TA508: Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee
Avelumab 08.01.05 Restricted Use NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Axicabtagene ciloleucel 08.01.05 Restricted Use NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
Axitinib 08.01.05 Restricted Use NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 08.01.03 Restricted Use NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Azithromycin 05.01.05 Restricted Use NICE evidence summary: Long-term azithromycin for non-CF bronchiectasis
Azithromycin 05.01.05 Restricted Use NICE evidence summary: Long-term azithromycin for CF
Baricitinib 10.01.03 Restricted Use NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Basiliximab 08.02.02 Restricted Use NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Basiliximab 08.02.02 Restricted Use NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Bee and Wasp Allergen Extracts 03.04.02 Restricted Use NICE TA246:Pharmalgen for the treatment of bee and wasp venom allergy
Bee and Wasp Venom 03.04.02 Restricted Use NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
Belimumab 10.01 Restricted Use NICE TA397 Belimumab for treating active autoantibody-positive system lupus erythematous
Bendamustine 08.01.01 Restricted Use NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
Bendamustine 08.01.01 Restricted Use NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Bendamustine 08.01.01 Restricted Use NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia.
Benralizumab 03.04.02 Restricted Use NICE TA565: Benralizumab for treating severe eosinophilic asthma
Bevacizumab 08.02.03 Restricted Use NICE Evidence summary: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.02.03 Restricted Use NICE TA560 TERMINATED APPRAISAL: Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Binimetinib 08.01.05 Restricted Use NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Bivalirudin 02.08.01 Restricted Use NICE TA230: Bivalirudin for the treatment of ST-segment-elevation myocardial infarction
Bivalirudin 02.08.01 Restricted Use NICE CG 94:Unstable angina and NSTEMI
Blinatumomab 08.02.03 Restricted Use NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Boceprevir 05.03.03.02 Non Formulary NICE TA253 WITHDRAWN: Boceprevir for the treatment of genotype 1 chronic hepatitis C
Bortezomib 08.01.05 Restricted Use NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
Bortezomib 08.01.05 Restricted Use NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Bortezomib 08.01.05 Restricted Use NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bortezomib 08.01.05 Restricted Use NICE TA453 TERMINATED APPRAISAL: Bortezomib for treating multiple myeloma after second or subsequent relapse
Bosutinib 08.01.05 Restricted Use NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Bosutinib 08.01.05 Restricted Use NICE TA576 TERMINATED APPRAISAL: Bosutinib for untreated chronic myeloid leukaemia
Botulinum neurotoxin type A 04.09.03 Restricted Use NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
Botulinum Toxin Type A 04.07.04.02 Restricted Use NICE TA260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Botulinum Toxin Type A 20.01 Restricted Use NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab vedotin 08.01.05 Restricted Use NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Restricted Use NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brentuximab vedotin 08.01.05 Restricted Use NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brigatinib 08.01.05 Restricted Use NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brodalumab 13.05.03 Restricted Use NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Burosumab 06.06.02 Non Formulary NICE HST8: Burosumab for treating X-linked hypophosphataemia in children and young people
Cabazitaxel 08.01.05 Restricted Use NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Restricted Use NICE TA516: Cabozantinib for treating medullary thyroid cancer
Cabozantinib 08.01.05 Restricted Use NICE TA582 TERMINATED APPRAISAL: Cabozantinib for previously treated advanced hepatocellular carcinoma
Cabozantinib 08.01.05 Restricted Use NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Restricted Use NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin for type 2 diabetes
Cangrelor 02.09 Non Formulary NICE TA351: Reducing Artherothrombotic Events
Cannabidiol 04.08.01 Restricted Use NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Cannabidiol 04.08.01 Restricted Use NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Capecitabine 08.01.03 Restricted Use NICE TA61: Capecitabine and tegafur with uracil for metastatic colorectal cancer
Capecitabine 08.01.03 Restricted Use NICE TA191: Capecitabine for the treatment of advanced gastric cancer
Capecitabine 08.01.03 Restricted Use NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Carbamazepine 04.02 Non Formulary NICE evidence summary: carbamazepine for behavioural disturbances in dementia
Carfilzomib 08.01.05 Restricted Use NICE TA457: Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Restricted Use NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Restricted Use NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Cefalexin 05.01.02.01 Formulary NICE CKS: lower UTI in women (July 2015)
Cemiplimab 08.01.05 Restricted Use NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
Cenegermin 11.04.02 Non Formulary NICE TA532 TERMINATED APPRAISAL: Cenegermin for treating neurotrophic keratitis
Ceritinib 08.01.05 Restricted Use NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Restricted Use NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Restricted Use NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab Pegol 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Restricted Use NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Cetirizine 03.04.01 Formulary NICE advice [ESUOM31]: Chronic urticaria: off-label doses of cetirizine
Cetuximab 08.01.05 Restricted Use NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Cetuximab 08.01.05 Restricted Use NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab 08.01.05 Restricted Use NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer
Chlorambucil 08.01.01 Restricted Use NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia.
Chlorambucil 08.01.01 Restricted Use NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia.
Chlordiazepoxide 04.01.02 Restricted Use NICE CG115: Alcohol-use disorders - diagnosis, assessment and management of harmful drinking and alcohol dependence
Ciclosporin 11.99.99.99 Restricted Use NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Restricted Use NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine 08.01.03 Restricted Use NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis
Clopidogrel 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Clopidogrel 02.09 Formulary NICE Evidence Summary ESUOM23: Clopidogrel for transient ischaemic attack
Cochlear implants for children and adults with severe to profound deafness 12.01 Restricted Use NICE TA566: Cochlear implants for children and adults with severe to profound deafness
Colesevelam 02.12 Non Formulary NICE Evidence Summary: Colesevelam for bile acid malabsorption
Colistimethate for nebulisation 05.01.07 Restricted Use NICE ESUOM25: Non-cystic fibrosis bronchiectasis: colistimethate sodium
Colistimethate inhaler 05.01.07 Restricted Use NICE: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
Crizotinib 08.01.05 Restricted Use NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
Crizotinib 08.01.05 Restricted Use NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Dabigatran 02.08.02 Restricted Use NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Restricted Use NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 02.08.02 Restricted Use NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
Dabrafenib 08.01.05 Restricted Use NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib 08.01.05 Restricted Use NICE TA564 TERMINATED APPRAISAL: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer
Dabrafenib 08.01.05 Restricted Use NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Dabrafenib 08.01.05 Restricted Use NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Restricted Use NICE TA 364: Daclatasvir for treating chronic hepatitis C
Dacomitinib 08.01.05 Restricted Use NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Daratumumab 08.01.05 Restricted Use NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Daratumumab 08.01.05 Restricted Use NICE TA454 TERMINATED APPRAISAL: Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Daratumumab 08.01.05 Restricted Use NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Darvadstrocel 01.05.03 Non Formulary NICE TA556 NOT RECOMMENDED: Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
Dasabuvir 05.03.03.02 Restricted Use NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Restricted Use NICE TA251: Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia
Dasatinib 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Debrisoft A5.07 Restricted Use NICE MTG17: Debrisoft for acute and chronic wounds
Decitabine 08.01.03 Non Formulary NICE TA270 TERMINATED APPRAISAL: Decitabine for leukaemia acute myeloid
Decitabine 08.01.03 Non Formulary NICE TA548 TERMINATED APPRAISAL: Decitabine for untreated acute myeloid leukaemia
Degarelix 08.03.04.02 Restricted Use NICE TA404 Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Restricted Use NICE TA204: Osteoporotic fractures - denosumab
Denosumab 06.06.02 Restricted Use NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Denosumab 06.06.02 Restricted Use NICE TA549 TERMINATED APPRAISAL: Denosumab for preventing skeletal-related events in multiple myeloma
Desmopressin 06.05.02 Formulary NICE Evidence summary: Desmopressin for nocturia and nocturnal polyuria in men with lower urinary tract symptoms
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA349: Diabetic Macular Oedema
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for multiple sclerosis
Dimethyl fumarate 13.05.03 Restricted Use NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
DIMETHYL SULPHOXIDE Bladder Instillation 50% 07.04.04 Restricted Use NICE Unlicensed Medicine Summary 26: Dimethyl Sulfoxide Bladder Instillation
Dinutuximab beta 08.02.03 Restricted Use NICE TA538: Dinutuximab beta for treating neuroblastoma
Dipyridamole 02.09 Restricted Use NICE TA210 Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Docetaxel 08.01.05 Restricted Use NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.05 Restricted Use NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Domperidone 04.06 Formulary NICE: Enteral feeds in children and young people: domperidone
Donepezil 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Doxorubicin Hydrochloride (Lipid formulation) 08.01.02 Restricted Use NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Restricted Use NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation
Dulaglutide 06.01.02.03 Formulary NICE Guidance NG28: Type 2 diabetes in adults - management
Dupilumab 13.05.01 Restricted Use NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Durvalumab 08.02.03 Restricted Use NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
Eculizumab 09.01.03 Restricted Use NICE evidence summary: eculizumab for prevention of C3 glomerulopathy post-transplant
Eculizumab 09.01.03 Restricted Use NICE HST1: Eculizumab for atypical haemolytic uraemic syndrome
Edoxaban 02.08.02 Restricted Use NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Edoxaban 02.08.02 Restricted Use NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation
Elbasvir and Grazoprevir 05.03.03.02 Restricted Use NICE TA413: Elbasvir-grazoprevir for treating chronic hepatitis C
Eliglustat 09.08.01 Restricted Use NICE HST5: Eliglustat for treating type 1 Gaucher disease
Eluxadoline 01.04.02 Restricted Use NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin for type 2 diabetes
Encorafenib 08.01.05 Restricted Use NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Entecavir 05.03.03.01 Restricted Use NICE TA153: Hepatitis B (chronic) - etecavir
Entecavir 05.03.03.01 Restricted Use NICE CG165: Hepatitis B (incorporates TA153)
Enzalutamide 08.03.04.02 Restricted Use NICE TA316: Enzalutamide for prostate cancer
Enzalutamide 08.03.04.02 Restricted Use NICE TA377: Enzalutamide for metastatic hromone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone 02.02.03 Restricted Use NICE CG 108: Chronic heart failure
Eribulin 08.01.05 Restricted Use NICE TA515 NOT RECOMMENDED NEGATIVE: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Eribulin 08.01.05 Restricted Use NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 08.01.05 Restricted Use NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Erlotinib 08.01.05 Restricted Use NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Ertugliflozin 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Ertugliflozin 06.01.02.03 Formulary NICE TA583:Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Erythromycin 05.01.05 Restricted Use NICE Evidence summary: Erythromycin for gastroparesis in adults
Etanercept 10.01.03 Restricted Use NICE TA373: Etanercept for JIA
Etanercept 10.01.03 Restricted Use NICE TA455: Plaque psoriasis in children and young people
Etanercept 10.01.03 Restricted Use NICE TA130: Rheumatoid arthritis
Etanercept 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Restricted Use NICE TA143: Ankylosing spondylitis
Etanercept 10.01.03 Restricted Use NICE TA195: After the failure of a TNF inhibitor
Etanercept 10.01.03 Restricted Use NICE TA103: Adult psoriasis
Etanercept 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Restricted Use NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 13.05.03 Restricted Use NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 13.05.03 Restricted Use NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
Etelcalcetide 06.06.01 Restricted Use NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Restricted Use NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy.
Everolimus 08.01.05 Restricted Use NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Evolocumab 02.12 Restricted Use NICE TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide prolonged release 06.01.02.03 Non Formulary NICE NG28
Exenatide prolonged release 06.01.02.03 Non Formulary NICE TAG 248- MR exenatide
Ezetimibe 02.12 Restricted Use NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Restricted Use NICE TA164: Hyperuricaemia - febuxostat
Finasteride 06.04.02 Formulary NICE CG97 Lower urinary tract symptoms
Fingolimod 08.02.04 Restricted Use NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludrocortisone 06.03.01 Formulary NICE Evidence Summary - postural hypotension
Flunarizine 20 Restricted Use NICE Unlicensed Evidence summary: Flunarizine for migraine prophylaxis
Fluocinolone intravitreal implant 11.04.01 Formulary BLACK - NOT RECOMMENDED NICE TA613: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy Technology appraisal guidance
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fluoxetine 04.03.03 Formulary NICE evidence summary: Fluoxetine for hypersexuality
Fluticasone furoate & vilanterol 03.02 Restricted Use NICE New Medicine Evidence Summary 34: Fluticasone furoate & vilanterol inhaler
Fondaparinux 02.08.01 Formulary NICE Guideline CG94: Unstable angina and NSTEMI - early management
FOSFOMYCIN Sachets 3g 20 Formulary NICE Evidence summary: Fosfomycin trometamol for multidrug resistant urinary tract infections
Fulvestrant 08.03.04.01 Non Formulary NICE TA503 NOT RECOMMENDED: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Galantamine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Galantamine MR capsule 04.11 Formulary Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (NICE TA217)
Gefitinib 08.01.05 Restricted Use NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine 08.01.03 Restricted Use NICE TA25: Gemcitabine for the treatment of pancreatic cancer
Gemcitabine 08.01.03 Restricted Use NICE TA116: Gemcitabine for the treatment of metastatic breast cancer
Gemtuzumab ozogamicini 08.01.05 Restricted Use NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Glatiramer Acetate 08.02.04 Restricted Use NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Glecaprevir and Pibrentasvir 05.03.03.02 Restricted Use NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
GLYCERYL TRINITRATE Ointment 0.2% 20 Non Formulary NICE Evidence summary: 0.2% glyceryl trinitrate ointment for chronic anal fissures
Glycopyrronium 20 Formulary NICE evidence summary: Glycopyrronium for hypersalivation
Glycopyrronium tablets 20 Non Formulary NICE Evidence Summary: glycopyrronium for hyperhidrosis
Golimumab 10.01.03 Restricted Use NICE TA220: Golimumab for the treatment of psoriatic arthritis
Golimumab 10.01.03 Restricted Use NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Restricted Use NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
Guselkumab 13.05.03 Restricted Use NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Holoclar® 11.08 Restricted Use NICE TA 467: Holoclar for treating limbal stem cell deficiency after eye burns
Ibandronic Acid 06.06.02 Restricted Use NICE TA464: Bisphosphonates for treating osteoporosis
Ibandronic Acid 06.06.02 Restricted Use NICE TA464: Bisphosphonates for treating osteoporosis
Ibrutinib 08.01.05 Restricted Use NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 08.01.05 Restricted Use NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibrutinib 08.01.05 Restricted Use NICE TA452 TERMINATED APPRAISAL: Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation
Idelalisib 08.01.05 Restricted Use NOT RECOMMENDED NICE TA604: Idelalisib for treating refractory follicular lymphoma
Idelalisib 08.01.05 Restricted Use NICE TA469 TERMINATED APPRAISAL: Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia
Idelalisib 08.01.05 Restricted Use NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
Iloprost 02.05.01 Restricted Use NICE Evidence Review ESUOM24: Critical limb ischaemia in peripheral vascular disease (intravenous iloprost)
Infliximab 10.01.03 Restricted Use NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Infliximab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Infliximab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 13.05.03 Restricted Use NICE TA134: Infliximab for the treatment of adults with psoriasis
Infliximab 01.05.03 Restricted Use NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Restricted Use NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 01.05.03 Non Formulary NICE HTTA339: Biosimilars of infliximab
Infliximab 01.05.03 Non Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Non Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 01.05.03 Non Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Inotuzumab ozogamicin 08.01.05 Restricted Use NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Interferon Alfa 08.02.04 Restricted Use Interferon Alfa - Chronic Hepatitis C
Interferon Beta-1a 08.02.04 Restricted Use NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta-1a 08.02.04 Restricted Use NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta-1b 08.02.04 Non Formulary BETAFERON NOT RECOMMENDED AS PER NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta-1b 08.02.04 Restricted Use NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Intrabeam radiotherapy system 08.03.04.01 Restricted Use NICE 501: Intrabeam radiotherapy system for adjuvant treatment of early breast cancer
Iodozyme® A5.03.02 Non Formulary NICE Medtech innovation briefing on Oxyzyme and Iodozyme
Ipilimumab 08.01.05 Restricted Use NICE TA400: Nivolumab in combination with ipilimumab for treating advanced
Ipilimumab 08.01.05 Restricted Use NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Restricted Use NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ivabradine 02.06.03 Restricted Use NICE CG126: Stable angina management
Ivabradine 02.06.03 Restricted Use NICE TA267: Ivabradine for chronic heart failure
Ivabradine 02.06.03 Restricted Use NICE Guidance on Stable Angina (2011)
Ivermectin 13.10.04 Restricted Use NICE Evidence summary: Ivermectin for difficult-to-treat scabies
Ixazomib 08.01.05 Restricted Use NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab 10.01.03 Restricted Use NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Ixekizumab 10.01.03 Restricted Use NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ixekizumab 13.05.03 Restricted Use NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ixekizumab 13.05.03 Restricted Use NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Ketamine 04.07.03 Restricted Use NICE Chronic pain: oral ketamine
Lamivudine 05.03.01 Restricted Use CG165: Chronic Hepatitis B
Lanadelumab 03.04.03 Restricted Use NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lapatinib 08.01.05 Restricted Use NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Ledipasvir and Sofosbuvir 05.03.03.02 Restricted Use NICE TA 363: Ledipasvir and Sofosbuvir for treating chronic Hepatitis C
Lenalidomide 08.02.04 Restricted Use NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Lenalidomide 08.02.04 Restricted Use NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Restricted Use NICE TA586:Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide 08.02.04 Restricted Use NICE TA454 TERMINATED APPRAISAL: Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Lenvatinib 08.01.05 Restricted Use NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Lenvatinib 08.01.05 Restricted Use NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
Lenvatinib 08.01.05 Restricted Use NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lesinurad 10.01.04 Non Formulary NICE TA506 NOT RECOMMENDED: Lesinurad for treating chronic hyperuricaemia in people with gout
Letermovir 05.03.02.02 Restricted Use NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant
Linaclotide 01.06.07 Restricted Use NICE CG61 : Irritable Bowel Syndrome in Adults
Liposomal Cytarabine–Daunorubicin 08.01.05 Restricted Use NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Liraglutide 06.01.02.03 Formulary NICE Guidance NG28: Type 2 diabetes in adults - management
Lubiprostone 01.06.07 Restricted Use NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lurasidone 04.02.01 Restricted Use NICE Evidence summary ESNM48: Schizophrenia - Lurasidone
Lusutrombopag 02.11 Restricted Use NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Lutetium (177Lu) oxodotreotide 08.01 Restricted Use NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
Magnesium Glycerophosphate 09.05.01.03 Formulary NICE: Evidence Summary: Magnesium glycerophosphate
Mannitol inhalation 03.07 Restricted Use NICE: Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Melatonin 04.01.01 Restricted Use NICE Evidence summary: Melatonin for sleep disorders in children with ADHD
Melatonin 04.01.01 Restricted Use NICE Evidence Summary - Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin
Melatonin 04.01.01 Restricted Use NICE Evidence Summary - Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin
Memantine 04.11 Restricted Use NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Mepolizumab 03.04.02 Restricted Use NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Metformin 06.01.02.02 Formulary NICE Evidence summary: Metformin for PCOS in women who are not planning pregnancy
Metformin 06.01.02.02 Formulary NICE Guideline [NG3]: Diabetes in pregnancy - management from preconception to the postnatal period (August 2015)
Methyldopa 02.05.02 Formulary NICE CKS - Hypertension in Pregnancy (Updated October 2019)
Methylnaltrexone 01.06.06 Non Formulary NICE TA468 TERMINATED APPRAISAL: Methylnaltrexone bromide for treating opioid-induced constipation
Methylprednisolone 06.03.02 Formulary NICE CG196 : Multiple Sclerosis; management in primary and secondary care ( Oct 2014).
MIDODRINE Tablets 2.5 mg, 5mg 20 Restricted Use NICE: Orthostatic hypotension: midodrine (ESNM61)
Midostaurin 08.01.05 Restricted Use NICE TA523: Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Restricted Use NICE TA235: Osteosarcoma - mifamurtide: guidance
Mifepristone 07.01.02 Restricted Use NICE Evidence summary ESUOM11: Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone)
Minocycline 05.01.03 Restricted Use NICE therapeutic topic: Minocycline
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for treating symptoms of overactive bladder
Misoprostol 07.01.01 Restricted Use NICE Evidence Summary ESUOM11: Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone)
Modafinil 04.04 Restricted Use NICE Evidence Summary: Modafinil for excessive daytime sleepiness in Parkinson’s disease
Modafinil 04.04 Restricted Use NICE Evidence Summary: Modafinil for fatigue in multiple sclerosis
Mycophenolate Mofetil 08.02.01 Restricted Use NICE Evidence summary: Mycophenolate for scleroderma
Mycophenolate Mofetil 08.02.01 Restricted Use NICE Evidence summary: Mycophenolate for SLE
Mycophenolate Sodium 08.02.01 Restricted Use NICE Evidence summary: Mycophenolate for scleroderma
Naftidrofuryl 02.06.04 Restricted Use NICE CG147: Peripheral arterial disease - diagnosis and management
Naftidrofuryl 02.06.04 Restricted Use NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Nalmefene 04.10.01 Restricted Use NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naltrexone/ bupropion 04.05.01 Non Formulary NICE TA494 NOT RECOMMENDED: Naltrexone–bupropion for managing overweight and obesity in adults
Natalizumab 08.02.04 Formulary NICE TA127: Multiple sclerosis - natalizumab
Nicorandil 02.06.03 Restricted Use NICE CG126: Stable angina management
Nifedipine 02.06.02 Formulary NICE CKS - Hypertension in Pregnancy (Updated October 2019)
Nilotinib 08.01.05 Restricted Use NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nilotinib 08.01.05 Restricted Use NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Nintedanib 03.11 Restricted Use NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 03.11 Non Formulary NICE TA347: Recurrent non-small-cell lung cancer
Niraparib 08.01.05 Restricted Use NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab 08.02.04 Restricted Use NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nivolumab 08.02.04 Restricted Use NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.02.04 Restricted Use NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 08.02.04 Restricted Use NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Nivolumab 08.02.04 Restricted Use NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Nivolumab 08.02.04 Restricted Use NICE TA400: Nivolumab in combination with ipilimumab for treating advanced
Nivolumab 08.02.04 Restricted Use NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab 08.02.04 Restricted Use NICE TA530 NOT RECOMMENDED: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Nusinersen 10.02 Restricted Use NICE TA588: Nusinersen for treating spinal muscular atrophy
Obeticholic acid 01.09.01 Restricted Use NICE TA443: Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Restricted Use NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 08.02.03 Restricted Use NICE TA343: Obinutuzumab with chlorambucil for CLL
Obinutuzumab 08.02.03 Restricted Use NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Ocrelizumab 08.02.04 Restricted Use NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocrelizumab 08.02.04 Restricted Use NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ofatumumab 08.02.03 Restricted Use NICE TA469 TERMINATED APPRAISAL: Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia
Ofatumumab 08.02.03 Restricted Use NICE TA470 TERMINATED APPRAISAL: Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia
Ofatumumab 08.02.03 Restricted Use NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
Olaparib 08.01.05 Restricted Use NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Olaparib 08.01.05 Restricted Use NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Olaratumab 08.01.05 Non Formulary NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Omalizumab 03.04.02 Restricted Use NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Restricted Use NICE TA278: Omalizumab for treating allergic asthma
Ombitasvir, Paritaprevir and Ritonavir 05.03.03.02 Restricted Use NICE TA 365: Ombitasvir/ paritaprevir/ ritonavir with or without dasabuvir for treating chronic hepatitis C
Omega-3-Marine Triglycerides 02.12 Non Formulary NICE: schizophrenia - omega-3 fatty acid medicines
Ondansetron 04.06 Restricted Use Ondansetron for vomiting in children with gastroenteritis- NICE evidence summary
Orlistat 04.05.01 Restricted Use NICE Guideline CG189: Obesity - identification, assessment and management
Oseltamivir 05.03.04 Restricted Use NICE TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza
Oseltamivir 05.03.04 Restricted Use NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Osimertinib 08.01.05 Restricted Use NICE TA416: 6. Osimertinib for treating locally advanced or metastatic EGFR T790 mutation-positive nonsmall-cell lung cancer
Oxaliplatin 08.01.05 Restricted Use NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Oxyzyme® A5.03.02 Non Formulary NICE Medtech innovation briefing on Oxyzyme and Iodozyme
Pabrinex® 09.06.02 Formulary NICE: Alcohol dependence - diagnosis, assessment and management
Pabrinex® 09.06.02 Formulary NICE: Management of alcohol-related physical complications
Paclitaxel 08.01.05 Restricted Use NICE TA389: Recurrent ovarian cancer
Paclitaxel - Albumin Bound Formulation 08.01.05 Restricted Use NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Padeliporfin 08.01.05 Non Formulary NICE TA546: Padeliporfin for untreated localised prostate cancer (Not Recommended)
Palbociclib 08.01.05 Restricted Use NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Palbociclib 08.01.05 Restricted Use NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panobinostat lactose anhydrous 08.02 Restricted Use NICE TA 380 Panobinostat
Patiromer 09.02.01.01 Restricted Use NICE TA623: Patiromer for treating hyperkalaemia
Pazopanib 08.01.05 Restricted Use NICE TA 215: Pazopanib in renal cell cancer
Pegaptanib Sodium 11.08.02 Non Formulary NICE guidance on pegaptanib in AMD (August 2008)
Peginterferon Alfa 08.02.04 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Restricted Use NICE TA 200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Restricted Use NICE TA 96: Hepatitis B - peginterferon alfa
Peginterferon Alfa 08.02.04 Restricted Use NICE TA 300: Hepatitis C - peginterferon alfa
Peginterferon beta-1a 08.02.04 Restricted Use NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
Pegloticase 20 Non Formulary NICE: TA291 - Pegloticase not recommended for severe chronic gout
Pegylated liposomal Irinotecan 08.01.05 Non Formulary NICE TA440 NOT RECOMMENDED NEGATIVE: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Pembrolizumab 08.01.05 Restricted Use NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pembrolizumab 08.01.05 Restricted Use NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Restricted Use NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Restricted Use NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Restricted Use NICE TA540 NOT RECOMMENDED: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pembrolizumab 08.01.05 Restricted Use NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Restricted Use NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Pembrolizumab 08.01.05 Restricted Use NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab 08.01.05 Restricted Use NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab 08.01.05 Restricted Use NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Restricted Use NICE TA570 TERMINATED APPRAISAL: Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Pemetrexed 08.01.03 Restricted Use NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Restricted Use NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Restricted Use NICE TA402:Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Restricted Use NICE TA135: Mesothelioma - pemetrexed disodium
Pentosan polysulfate sodium 07.04.03 Restricted Use NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome
Perampanel 04.08.01 Restricted Use NICE evidence summary
Perampanel 04.08.01 Restricted Use NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Restricted Use NICE TA424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pertuzumab 08.01.05 Restricted Use NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pertuzumab 08.01.05 Restricted Use NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pimecrolimus 1% 13.05.03 Restricted Use NICE TA82: Tacrolimus and pimecrolimus for atopic eczema.
Pirfenidone 03.11 Restricted Use NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pitolisant 04.01.01 Restricted Use NICE Evidence summary [ES8]: Pitolisant - Narcolepsy with or without cataplexy in adults
Pixantrone 08.01.02 Restricted Use NICE TA306:Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma
Pomalidomide 08.02.04 Restricted Use NICE New Medicine Evidence Summary 32: pomalidomide
Pomalidomide 08.02.04 Restricted Use NICE TA388: Pomalidomide for myeloma
Ponatinib 08.01.05 Restricted Use NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Restricted Use NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
Pregabalin 04.02.03 Restricted Use NICE CG113: Generalised anxiety disorder and panic disorder in adults - management
Promethazine 03.04.01 Restricted Use NICE Evidence summary: Promethazine for rapid tranquillisation in mental health settings
Prucalopride 01.06.07 Restricted Use NICE TA211: Constipation (women) - prucalopride
Quetiapine 04.02.01 Restricted Use NICE Evidence summary ESUOM12 : Quetiapine for generalised anxiety disorder
Radium- 223 chloride 08.03.04.02 Restricted Use NICE TA376: Radium 223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene Hydrochloride 06.04.01.01 Restricted Use Drugs for osteoporosis (NICE TA160)
Ramipril 02.05.05.01 Formulary NICE evidence summary ESUOM45: Ramipril for the symptoms of peripheral arterial disease
Ramucirumab 08.01.05 Non Formulary NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
Ranolazine 02.06.03 Restricted Use NICE GC126: Stable angina management
ReCell Spray on Skin system A5.04 Non Formulary NICE MTG21: ReCell Spray‑On Skin system for burn injury
Regorafenib 08.01.05 Restricted Use NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Regorafenib 08.01.05 Restricted Use NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Reslizumab 03.04.02 Restricted Use NICE TA479: Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Restricted Use NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.05 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribociclib 08.01.05 Restricted Use NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Ribociclib 08.01.05 Restricted Use NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Rifaximin 05.01.07 Restricted Use NICE TA337 Rifaximin for preventing episodes of overt hepatic encephalopathy ( March 2015)
Rifaximin 05.01.07 Restricted Use NICE evidence summary: Rifaximin for pouchitis ( March 2014)
Riluzole 04.09.03 Restricted Use NICE TA20: Riluzole for the treatment of Motor Neurone Disease
Risankizumab 13.05.03 Restricted Use NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis
Risedronate 06.06.02 Restricted Use NICE TA464: Bisphosphonates for treating osteoporosis
Risedronate 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Rituximab 08.02.03 Restricted Use Rituximab for ITP-NICE evidence summary
Rituximab 08.02.03 Restricted Use NICE guidelines for rituximab
Rituximab (rheumatology) 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Restricted Use NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Restricted Use NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Restricted Use NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Restricted Use NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Restricted Use NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivastigmine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Roflumilast 03.03.03 Restricted Use NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Restricted Use NICE TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
Rucaparib 08.01.05 Restricted Use NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Ruxolitinib 08.01.05 Restricted Use NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril / valsartan 02.05.05.02 Restricted Use NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab 10.01.03 Restricted Use NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Scheriproct® 01.07.02 Non Formulary BNF: Haemorrhoids Treatment Summary
Secukinumab 10.01.03 Restricted Use NICE TA445: Secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Restricted Use NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Semaglutide 06.01.02.03 Formulary NICE Guidance NG28: Type 2 diabetes in adults - management
Sildenafil 02.05.01 Restricted Use NICE Evidence summary: Sildenafil for digital ulcers
Simeprevir 05.03.03.02 Restricted Use NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Sipuleucel- T 20 Non Formulary NICE TA322: Sipuleucel-T for prostate cancer
Sodium Valproate 04.02 Non Formulary NICE evidence summary: valproate for behavioural disturbances in dementia
Sodium zirconium cyclosilicate 09.02.01.01 Restricted Use NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Sofosbuvir 05.03.03.02 Restricted Use NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir and Velpatasvir 05.03.03.02 Restricted Use NICE TA430 Sofosbuvir–velpatasvir for treating chronic hepatitis C
Somatropin 06.05.01 Restricted Use NICE TA64: Growth hormone deficiency (adults)
Somatropin 06.05.01 Restricted Use NICE TA188: Somatropin for growth failure in children
Sorafenib 08.01.05 Restricted Use NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sorafenib 08.01.05 Restricted Use NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Sotagliflozin 06.01.02.03 Formulary NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes
Sunitinib 08.01.05 Restricted Use NICE TA179: Sunitinib for the treatment of gastro-intestinal stromal tumours
Sunitinib 08.01.05 Restricted Use NICE TA169: Sunitinib for advanced or metastatic renal cell carcinoma
Sunitinib 08.01.05 Restricted Use NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Tacrolimus 13.05.03 Restricted Use NICE TA82: Tacrolimus and pimecrolimus for atopic eczema
Tadalafil 07.04.05 Formulary NICE: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)
Talimogene laherparepvec 08.01.05 Restricted Use NICE TA410 Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capecitabine and tegafur with uracil for metastatic colorectal cancer
Telaprevir 05.03.03.02 Non Formulary NICE TA252: Telaprevir in hepatitis C
Temozolomide 08.01.05 Restricted Use NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Temozolomide 08.01.05 Restricted Use NICE TA23: Temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Tenofovir Disproxil 05.03.01 Restricted Use NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Formulary NICE TA 303: Teriflunomide for relapsing remitting MS
Thiamine 09.06.02 Formulary NICE: Alcohol dependence - diagnosis, assessment and management
Thiamine 09.06.02 Formulary NICE: Management of alcohol-related physical complications
Ticagrelor 02.09 Restricted Use NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Restricted Use NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tildrakizumab 13.05.03 Restricted Use NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
Tirofiban 02.09 Restricted Use NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Tisagenlecleucel 08.01.05 Restricted Use NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Tisagenlecleucel 08.01.05 Restricted Use NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Tivozanib 08.01.05 Restricted Use NICE TA 512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 05.01.04 Restricted Use NICE: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
Tocilizumab 10.01.03 Restricted Use NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
Tocilizumab 10.01.03 Restricted Use NICE TA373: Tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Restricted Use NICE TA238: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
Tocilizumab 10.01.03 Restricted Use NICE TA375: Tocilizumab for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Restricted Use NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib 10.01.03 Restricted Use NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib 10.01.03 Restricted Use NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib 10.01.03 Restricted Use NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tolvaptan 06.05.02 Restricted Use NICE TA358 Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Restricted Use NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
Topotecan 08.01.05 Restricted Use NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.05 Restricted Use NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma
Trametinib 08.01.05 Restricted Use NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trametinib 08.01.05 Restricted Use NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Trametinib 08.01.05 Restricted Use NICE TA564 TERMINATED APPRAISAL: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer
Tranexamic Acid 02.11 Formulary NICE Evidence Summary ESUOM1: Tranexamic acid for significant haemorrhage following trauma
Trastuzumab 08.01.05 Restricted Use NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Trastuzumab 08.01.05 Restricted Use NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
Trastuzumab 08.01.05 Restricted Use NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
Trastuzumab emtansine 08.01.05 Restricted Use NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trifluridine and Tipiracil 08.01.03 Restricted Use NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
UroLift system 20 Non Formulary NICE MTG26: UroLift for treating symptoms of BPH
Ustekinumab 10.01.03 Restricted Use NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 01.05.03 Restricted Use NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 13.05.03 Restricted Use NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab 13.05.03 Restricted Use NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Vandetanib 08.01.05 Non Formulary NICE TA550 NOT RECOMMENDED NEGATIVE: Vandetanib for treating medullary thyroid cancer
Varenicline 04.10.02 Restricted Use NICE TA123: Varenicline for smoking cessation
Vedolizumab 01.05.03 Restricted Use NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Restricted Use NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Restricted Use NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Venetoclax 08.01.05 Restricted Use NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax 08.01.05 Restricted Use NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Verteporfin 11.08.02 Restricted Use NICE TA 68: Photodynamic therapy for age related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)
Vismodegib 08.01.05 Restricted Use NICE TA489 TERMINATED APPRAISAL: Vismodegib for treating basal cell carcinoma
Vortioxetine 04.03.03 Restricted Use Vortioxetine for treating major depressive episodes (NICE TA367)
Zanamivir inhalation 05.03.04 Restricted Use NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Zanamivir inhalation 05.03.04 Restricted Use NICE TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza
Zoledronic Acid 06.06.02 Restricted Use NICE TA464: Bisphosphonates for treating osteoporosis
Zolpidem 04.01.01 Restricted Use NICE TA77 : Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77 :Zaleplon, zolpidem and zopiclone for the management of insomnia
Cambridgeshire and Peterborough